Open AccessCircular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer
Author(s) -
Yutao Liu,
Xiaohong Han,
Puyuan Xing,
Xingsheng Hu,
Xuezhi Hao,
Yan Wang,
Junling Li,
Zhishang Zhang,
Zhihao Yang,
Yue Shi
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.05.22
Subject(s) - gefitinib , lung cancer , medicine , biomarker , epidermal growth factor receptor , circular rna , oncology , microarray , cancer research , tyrosine kinase inhibitor , cancer , rna , biology , gene , gene expression , genetics
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become important treatment options for non-small cell lung cancer (NSCLC) patients with EGFR sensitive mutation. However, the detection of EGFR driver mutation is impeded by the lack of adequate tumor tissues, histopathological type, long detection period, and the heterogeneity of a tumor. Therefore, it is necessary to develop a more convenient method to guide the clinical use of EGFR-TKI. Circular RNAs (circRNAs) are characterized as a closed structure with covalently joined ends resistant to exonucleases may be a potential biomarker. In the present study, we aimed to screen circRNAs that may be associated with the efficacy of EGFR-TKI.